Pfizer CEO, Regeneron co-founder headline 2024 annual Wharton Undergraduate Healthcare Conference thedp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedp.com Daily Mail and Mail on Sunday newspapers.
For the first time since 2019, finalists in this year's Regeneron ISEF competition gathered to exchange pins representing their home countries and states.
Greek at helm of organization providing new hope for Alzheimer’s patients
Search for:
It has been the holy grail of the international scientific community for decades. Some 115 years since German neuropathologist Alois Alzheimer conducted the autopsy that allowed him to identify the disease which came to bear his name, around 50 million people around the world afflicted by it are still waiting for a cure.
Alzheimer’s is among the top 10 causes of death in the United States, but it is the only one of those causes that cannot be prevented, cured or even slowed down. A disease that costs the American medical system alone 1 trillion dollars a year and is estimated to affect as many as 130 million people by 2050 remains very much an unsolved puzzle for the medical and pharmaceutical sectors.
Regeneron’s early stage bispecific shows promise
Bispecifics and antibody drug conjugates will challenge CAR-Ts
The potentially revolutionary nature of CAR-Ts has made them the hottest properties in haemato-oncology in recent years, but a wave of bispecific antibody therapies look set to challenge them.
Representing an evolution of the well-established monoclonal antibody platform, bispecifics can hit two or more cell surface targets. This approach could see them match the clinical performance of CAR-Ts, but with a far easier and lower cost manufacturing process, and without the risk of serious side effects including cytokine-release syndrome (CRS).
Regeneron is one many companies developing bispecifics, and on Saturday at the ASH 2018 congress in San Diego, unveiled phase 1 proof of concept data for its REGN1979 in relapsed or refractory (R/R) follicular lymphoma and diffuse large B-cell lymphoma (DLBCL), the two most common types of Non-Hodgkins Lymphoma (NHL).